Protagonist Therapeutics, Inc (PTGX) Free cash flow 2016–2025
Protagonist Therapeutics, Inc (PTGX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$56.1MFY2025 · since FY2016: -$30.3M → $56.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $56.1M | -69.3% |
| FY2024 | $182.8M | +358.0% |
| FY2023 | -$70.8M | +35.0% |
| FY2022 | -$108.9M | +0.0% |
| FY2021 | -$109.0M | -49.4% |
| FY2020 | -$73.0M | -71.7% |
| FY2019 | -$42.5M | +15.7% |
| FY2018 | -$50.4M | -1673.1% |
| FY2017 | $3.2M | +110.6% |
| FY2016 | -$30.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PTGX financial trends
PTGX RevenuePTGX Net incomePTGX Net marginPTGX Gross profitPTGX Gross marginPTGX Operating incomePTGX Operating marginPTGX Operating cash flowPTGX Capital expendituresPTGX Return on equityPTGX Stock buybacksPTGX Dividends paidPTGX Total assetsPTGX Total liabilitiesPTGX Shareholders’ equityPTGX overview →